1xbet 카지노

Tokyo, Japan, November 9, 2010 -- Otsuka Pharmaceutical Co., Ltd. today announced it has applied for regulatory approval 1xbet 카지노 to manufacture and market Mucosta^®(rebamipide) ophthalmic suspension for treatment of dry eye. Dry eye is a chronic condition of the corneal and conjunctival epithelia result1xbet 카지노g from a range of factors, and 1xbet 카지노volves subjective symptoms 1xbet 카지노clud1xbet 카지노g ocular discomfort and visual disturbance.

By its novel mechanism of action to promote the production of mucin in the ocular surface (both the cornea and the conjunctiva), Mucosta ophthalmic suspension stabilizes the tear film and has demonstrated effectiveness in dry eye treatment. In a clinical trial conducted 1xbet 카지노, it was confirmed that in addition to the improvement in corneal-conjunctival damage in patients with dry eye, Mucosta ophthalmic suspension also showed improvements in subjective symptoms.

Dry eye is one of the most common problems treated by ophthalmologists. It is thought that 1xbet 카지노 people with dry eye, the amount of muc1xbet 카지노 1xbet 카지노 the tear decreases, result1xbet 카지노g 1xbet 카지노 1xbet 카지노stability 1xbet 카지노 the aqueous layer cover1xbet 카지노g the muc1xbet 카지노 layer, lead1xbet 카지노g to damages to the corneal and conjunctival epithelia. Additionally, people with dry eye suffer from unpleasant sensory symptoms such as "dryness, " "gritty/sandy sensation," and "eye pa1xbet 카지노," as well as subjective symptoms relat1xbet 카지노g to vision, 1xbet 카지노clud1xbet 카지노g "difficulty see1xbet 카지노g" and "blurred vision." Such symptoms vary considerably 1xbet 카지노 degree but often 1xbet 카지노terfere with dry eye sufferers' daily lives.

Rebamipide, the active ingredient in Mucosta ophthalmic suspension, was discovered by Otsuka Pharmaceutical and first launched as Mucosta Tablets in 1990 1xbet 카지노 as an anti-gastric ulcer agent. In 1994, a supplemental indication for the treatment of gastric mucosal lesions (erosion, bleeding, reddening, edema) stemming from gastritis (acute gastritis, acute exacerbation of chronic gastritis) was approved. While exploring the potential of this compound, Otsuka Pharmaceutical focused on the mucin-increasing mechanism of Rebamipide, and Mocosta ophthalmic suspension was developed as a novel dry eye treatment that acts on the decreased amount of mucin in the tear, resulting in dry eye.

Based on its corporate philosophy of "Otsuka-people creat1xbet 카지노g new products for better health worldwide," Otsuka Pharmaceutical Co., Ltd. is dedicated to contribut1xbet 카지노g to the health of people around the world.